Antiviral Activity of AZD7295 in HCV Carriers

Phase 1

Completed

• Conditions: Hepatitis C
• Interventions: Drug: Placebo; Drug: AZD7295

• Registration Number: NCT00781976
• Lead Sponsor: Arrow Therapeutics

Brief Summary

PK, safety study of AZD7295 in HCV carriers

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-10-28
• Study First Submitted QC: 2008-10-28
• Study First Posted: 2008-10-29
• Study Start: 2008-11
• Status Verified: 2010-03
• Primary Completion: 2010-03
• Study Completion: 2010-03
• Last Update Submitted: 2010-03-30
• Last Update Posted: 2010-03-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

• HCV carrier

Exclusion Criteria

• concurrent medications

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Placebo	-
2	AZD7295	-

Primary Outcome Measures

Name	Time	Method
Plasma AZD7295 concentrations and pharmacokinetics	5 days

Trial Locations

Locations (1)

Prof Ed Gane; 🇳🇿 Auckland, New Zealand